Author

Francis Megraud

H. pylori: History of a breakthrough
H. pylori: History of a breakthrough

Francis Megraud

H. Pylori vaccination: Rrelevant progress?
H. Pylori vaccination: Rrelevant progress?

Francis Megraud

H. pylori testing: Is breathless fine?
H. pylori testing: Is breathless fine?

Francis Megraud

HELICOBACTER PYLORI RESISTANCE TO ANTIBIOTICS IN EUROPE IN 2018 AND ITS RELATIONSHIP TO ANTIBIOTIC CONSUMPTION IN THE COMMUNITY
HELICOBACTER PYLORI RESISTANCE TO ANTIBIOTICS IN EUROPE IN 2018 AND ITS RELATIONSHIP TO ANTIBIOTIC CONSUMPTION IN THE COMMUNITY

Francis Megraud  et al.

Management of Helicobacter pylori infection—the Maastricht V/Florence Consensus Report
Management of Helicobacter pylori infection—the Maastricht V/Florence Consensus Report

Francis Megraud  et al.

Panel discussion: 40 years of H. pylori - Back to the future
Panel discussion: 40 years of H. pylori - Back to the future

Francis Megraud  et al.

LEUKAEMIA INHIBITORY FACTOR SIGNALLING FOR TARGETING CANCER STEM CELLS IN GASTRIC ADENOCARCINOMA
LEUKAEMIA INHIBITORY FACTOR SIGNALLING FOR TARGETING CANCER STEM CELLS IN GASTRIC ADENOCARCINOMA

Francis Megraud  et al.

ASSESSMENT OF FIRST-LINE TREATMENT IN GREECE: DATA FROM THE EUROPEAN REGISTRY ON HELICOBACTER PYLORI MANAGEMENT (HP-EUREG)
ASSESSMENT OF FIRST-LINE TREATMENT IN GREECE: DATA FROM THE EUROPEAN REGISTRY ON HELICOBACTER PYLORI MANAGEMENT (HP-EUREG)

Francis Megraud  et al.

Management of epithelial precancerous conditions and lesions in the stomach (MAPS II): European Society of Gastrointestinal Endoscopy (ESGE), European Helicobacterand Microbiota Study Group (EHMSG), European Society of Pathology (ESP), and Sociedade Portu
Management of epithelial precancerous conditions and lesions in the stomach (MAPS II): European Society of Gastrointestinal Endoscopy (ESGE), European Helicobacterand Microbiota Study Group (EHMSG), European Society of Pathology (ESP), and Sociedade Portu

Francis Megraud  et al.

SIXTH-LINE ERADICATION THERAPY AGAINST HELICOBACTER PYLORI INFECTION: PRELIMINARY DATA FROM THE EUROPEAN REGISTRY ON THE MANAGEMENT OF HELICOBACTER PYLORI INFECTION (HP-EUREG)
SIXTH-LINE ERADICATION THERAPY AGAINST HELICOBACTER PYLORI INFECTION: PRELIMINARY DATA FROM THE EUROPEAN REGISTRY ON THE MANAGEMENT OF HELICOBACTER PYLORI INFECTION (HP-EUREG)

Francis Megraud  et al.

Joint ESPGHAN/NASPGHAN Guidelines for the Management of Helicobacter pylori in Children and Adolescents (Update 2016)
Joint ESPGHAN/NASPGHAN Guidelines for the Management of Helicobacter pylori in Children and Adolescents (Update 2016)

Francis Megraud  et al.

REAL-WORLD COMPARATIVE EFFECTS OF THREE-IN-ONE SINGLE CAPSULE BISMUTH QUADRUPLE THERAPY VS. NON-BISMUTH QUADRUPLE CONCOMITANT THERAPY: INTERIM ANALYSIS OF THE EUROPEAN REGISTRY ON H. PYLORI MANAGEMENT (HP-EUREG)
REAL-WORLD COMPARATIVE EFFECTS OF THREE-IN-ONE SINGLE CAPSULE BISMUTH QUADRUPLE THERAPY VS. NON-BISMUTH QUADRUPLE CONCOMITANT THERAPY: INTERIM ANALYSIS OF THE EUROPEAN REGISTRY ON H. PYLORI MANAGEMENT (HP-EUREG)

Francis Megraud  et al.

SAFETY OF THE TREATMENT OF H. PYLORI INFECTION: EXPERIENCE FROM THE EUROPEAN REGISTRY ON H. PYLORI MANAGEMENT (HP-EUREG) ON 22,000 PATIENTS
SAFETY OF THE TREATMENT OF H. PYLORI INFECTION: EXPERIENCE FROM THE EUROPEAN REGISTRY ON H. PYLORI MANAGEMENT (HP-EUREG) ON 22,000 PATIENTS

Francis Megraud  et al.

BISMUTH QUADRUPLE THREE-IN-ONE SINGLE CAPSULE: 3 OR 4 TIMES DAILY? SUB-ANALYSIS OF THE SPANISH DATA OF THE EUROPEAN REGISTRY ON H. PYLORI MANAGEMENT (HP-EUREG)
BISMUTH QUADRUPLE THREE-IN-ONE SINGLE CAPSULE: 3 OR 4 TIMES DAILY? SUB-ANALYSIS OF THE SPANISH DATA OF THE EUROPEAN REGISTRY ON H. PYLORI MANAGEMENT (HP-EUREG)

Francis Megraud  et al.

ANTIBIOTIC RESISTANCE TRENDS OF HELICOBACTER PYLORI NAÏVE PATIENTS IN THE PERIOD 2013-2020: ANALYSIS OF THE EUROPEAN REGISTRY ON H. PYLORI MANAGEMENT (HP-EUREG)
ANTIBIOTIC RESISTANCE TRENDS OF HELICOBACTER PYLORI NAÏVE PATIENTS IN THE PERIOD 2013-2020: ANALYSIS OF THE EUROPEAN REGISTRY ON H. PYLORI MANAGEMENT (HP-EUREG)

Francis Megraud  et al.

EUROPEAN REGISTRY ON H. PYLORI MANAGEMENT (HP-EUREG): ANALYSIS OF EMPIRICAL SECOND-LINE TREATMENTS IN EUROPE
EUROPEAN REGISTRY ON H. PYLORI MANAGEMENT (HP-EUREG): ANALYSIS OF EMPIRICAL SECOND-LINE TREATMENTS IN EUROPE

Francis Megraud  et al.

ROOM FOR IMPROVEMENT IN THE TREATMENT OF HELICOBACTER PYLORI INFECTION: LESSONS FROM THE EUROPEAN REGISTRY ON H. PYLORI MANAGEMENT (HP-EUREG)
ROOM FOR IMPROVEMENT IN THE TREATMENT OF HELICOBACTER PYLORI INFECTION: LESSONS FROM THE EUROPEAN REGISTRY ON H. PYLORI MANAGEMENT (HP-EUREG)

Francis Megraud  et al.

EXPERIENCE WITH RIFABUTIN-CONTAINING THERAPY IN 426 PATIENTS FROM THE EUROPEAN REGISTRY ON H. PYLORI MANAGEMENT (HP-EUREG)
EXPERIENCE WITH RIFABUTIN-CONTAINING THERAPY IN 426 PATIENTS FROM THE EUROPEAN REGISTRY ON H. PYLORI MANAGEMENT (HP-EUREG)

Francis Megraud  et al.

EUROPEAN REGISTRY ON H. PYLORI MANAGEMENT (HP-EUREG): ANALYSIS OF 1,782 EMPIRICAL RESCUE THERAPIES ON THIRD AND SUBSEQUENT LINES
EUROPEAN REGISTRY ON H. PYLORI MANAGEMENT (HP-EUREG): ANALYSIS OF 1,782 EMPIRICAL RESCUE THERAPIES ON THIRD AND SUBSEQUENT LINES

Francis Megraud  et al.

EFFECTIVENESS OF FIRST-LINE HELICOBACTER PYLORI ERADICATION TREATMENTS IN SPAIN: RESULTS FROM THE EUROPEAN REGISTRY ON H. PYLORI MANAGEMENT (HP-EUREG)
EFFECTIVENESS OF FIRST-LINE HELICOBACTER PYLORI ERADICATION TREATMENTS IN SPAIN: RESULTS FROM THE EUROPEAN REGISTRY ON H. PYLORI MANAGEMENT (HP-EUREG)

Francis Megraud  et al.

Item 1 - 20 / 51
1
2 3